A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

NCT05838521 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Sacituzumab govitecan

Sponsor

Yale University

Collaborators

[object Object]